From Nasdaq.: 2025-04-01 17:48:00

INmune Bio, Inc. is presenting findings from its MINDFuL Phase II trial at the International Conference on Alzheimer’s and Parkinson’s Diseases. The trial focuses on early Alzheimer’s disease patients with confirmed biomarkers of inflammation and enrolled 208 patients with an average age of 72. Participants were randomized to receive XPro™ or placebo for 23 weeks. Preliminary data showed 69.2% of participants carried the APOE e4 allele. Topline results are expected in June 2025. INMB closed at $7.59 on Tuesday.



Read more at Nasdaq.: INmune Bio Presents MINDFuL Trial Data At AD/PD 2025